Feray Aras

Dr. Feray Aras


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
FAFeray Aras
Feray Aras
MPMurtaza Parvizi
Murtaza Parvizi
ONOlcay Ak Nalbant
Olcay Ak Nalbant
VOVolkan Ozkol
Volkan Ozkol
EKEngin Kut
Engin Kut
This study primarily aimed to assess whether baseline [(18)F] fluorodeoxyglucose (FDG) PET/CT metabolic parameters—including SUVmax, metabolic tumor volume (MTV), and total lesion glycolysis (TLG)—can predict tumor regression grade (TRG) and survival in patients with locally advanced rectal cancer (LARC) undergoing neoadjuvant chemoradiotherapy (nCRT). In addition, secondary analyses were performed to identify other clinical and pathological variables associated with treatment response and prognosis. This retrospective study included patients diagnosed with LARC who underwent nCRT followed by surgical resection between 2014 and 2023. Pre-treatment staging with F-18 FDG PET/CT was performed for all patients. Postoperative pathological response was assessed using the TRG system. Patients were categorized into two groups: complete responders (TRG1) and incomplete responders (TRG2–5). Demographic characteristics, PET/CT metabolic parameters (SUVmax, MTV, TLG), Carcinoembryonic antigen (CEA), Carbohydrate antigen 19 − 9 (CA19-9), and histopathological features (perforation, lymphovascular invasion [LVI], and perineural invasion [PNI]) were compared between the groups. Statistical analyses included chi-square tests, Mann–Whitney U tests, logistic regression models with odds ratios (ORs), and Kaplan–Meier survival analysis. A total of 151 patients were included. A statistically significant difference was found between TRG1 and TRG2-5 groups regarding family history (p = 0.034), CEA at diagnosis (p = 0.002), Ca19.9 after radiotherapy (p = 0.045), and presence of concurrent chemotherapy (CC) (p = 0.004). Significant differences were also observed in postoperative pathological features, including perforation (p = 0.045), LVI (p = 0.023), PNI (p = 0.031), and post-operative CEA levels (p = 0.001). In terms of outcomes, TRG1 was associated with better survival (p = 0.001), longer disease-free survival (p = 0.001), and overall survival (p = 0.001). Logistic regression identified independent predictors of complete response (TRG1): family history (OR: 5.08, p = 0.027), post-RT CEA (OR: 0.61, p = 0.015), post-op CEA (OR: 1.13, p = 0.012), perforation (OR: 20.93, p = 0.033), LVI (OR: 0.33, p = 0.042), and PNI (OR: 0.49, p = 0.045). Kaplan–Meier analysis demonstrated significantly longer overall survival in patients with TRG1 compared to TRG2–5 (log-rank p = 0.001). Similarly, disease-free survival was significantly better in the TRG1 group (log-rank p = 0.001). In the multivariate Cox regression model, TRG1 (HR: 0.41; 95% CI: 0.26–0.66; p = 0.001), CC (HR: 0.62; 95% CI: 0.39–0.98; p = 0.039), and absence of perforation (HR: 0.51; 95% CI: 0.28–0.95; p = 0.034) were found to be independent predictors of improved survival. Baseline F-18 FDG PET/CT parameters, including SUVmax, MTV, and TLG, were not predictive of TRG or survival in patients with LARC undergoing neoadjuvant chemoradiotherapy. However, clinical and pathological variables such as family history, post-treatment CEA levels, perforation, lymphovascular invasion, and perineural invasion were significantly associated with TRG1. TRG1, histopathological subtype, perforation, and CC were also found to be independent predictors of survival. These findings suggest that while FDG-PET/CT may have limited utility in predicting treatment response, certain clinical and pathological features remain critical for outcome assessment.

1 April 2021 in Journal of Clinical and Analytical Medicine
Verified
Journal Article
Closed access
FAFeray Aras
Feray Aras
EBElvan Sayit Bilgin
Elvan Sayit Bilgin

1 January 2023 in Journal of Clinical and Analytical Medicine
Verified
Journal Article
Open access
FAFeray Aras
Feray Aras

20 September 2023 in Experimental Biomedical Research
Verified
Journal Article
Closed access
FAFeray Aras
Feray Aras
CTCumhur Murat TULAY
Cumhur Murat TULAY

15 March 2024 in Experimental Biomedical Research
Verified
Journal Article
Open access
PDF file
FAFeray Aras
Feray Aras
Aim: To evaluate the relationship between renal abnormalities detected by 99mTc-Dimercaptosuccinic acid (99mTc-DMSA) scans and glomerular filtration rate estimated by γ-camera method using 99mTc-DTPA (Diethylene-triamine-pentaacetate dynamic renal scintigraphy) in patients with renal parenchymal scarring. Methods: We selected children who were followed up in our Pediatric Clinic for recurrent urinary tract infections and developed unilateral renal parenchymal scarring after these infections. We compared 99mTc-DMSA difference rates, glomerular filtration rate (GFR) calculated by γ -camera method and 99mTc-DTPA difference rates in the affected kidney. Results: Of the 23 patients, 14 (60.9%) were female and 9 (39.1%) were male. The mean age of the patients was 10.41 ± 4.49 years. In the comparison of 99mTc-DMSA scans and glomerular filtration rate calculated by γ -camera method using 99mTc-DTPA in the renal parenchymal scarring kidney, there was no significant difference in the Tc-99m-DTPA (%) difference rates between the scarring and non-scarring kidney (p=0.750). However, there was a significant decrease in GFR (ml/min) values in the scarring kidney compared to the non-scarring kidney (p=0.025). Conclusions: We found that GFR measurement provides earlier information than other methods in assessing renal function with DTPA and DMSA in patients with scarred kidneys, before irreversible loss of function occurs. GFR value is statistically more significant than DTPA and DMSA evaluation.